Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience

A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. is developing potentially life-changing therapies for patients with cancer and diabetes that have limited treatment options. The company is working with world-class institutions in developing new drugs from the company’s pipeline of gene therapy candidates in order to provide novel treatment approaches. Its oncology program utilizes its proprietary non-viral ONCOPREX® Nanoparticle Delivery System, which Genprex believes is the first systemic gene therapy delivery platform used for cancer in humans.